在人类免疫缺陷病毒感染背景下的心血管疾病管理进展。
Advances in the Management of Cardiovascular Disease in the Setting of Human Immunodeficiency Virus.
机构信息
Department of Medicine, University of California, San Francisco, CA, USA; Division of Cardiology, Zuckerberg San Francisco General, San Francisco, CA, USA.
Department of Medicine, University of California, San Francisco, CA, USA; Division of Cardiology, Zuckerberg San Francisco General, San Francisco, CA, USA.
出版信息
Infect Dis Clin North Am. 2024 Sep;38(3):517-530. doi: 10.1016/j.idc.2024.04.006. Epub 2024 Jun 12.
Abstract
This state-of-the art review discusses the underlying mechanisms that contribute to atherosclerotic cardiovascular disease, heart failure and arrhythmias among people with human immunodeficiency virus (HIV), risk prediction and prevention, management, and outstanding research questions, including a discussion of how the Randomized Trial to Prevent Vascular Events in HIV may inform clinical practice.
摘要
这篇最先进的综述讨论了导致人类免疫缺陷病毒（HIV）感染者发生动脉粥样硬化性心血管疾病、心力衰竭和心律失常的潜在机制、风险预测和预防、管理以及未解决的研究问题，包括讨论随机预防 HIV 血管事件试验（Randomized Trial to Prevent Vascular Events in HIV）如何为临床实践提供信息。
相似文献
1
Advances in the Management of Cardiovascular Disease in the Setting of Human Immunodeficiency Virus.在人类免疫缺陷病毒感染背景下的心血管疾病管理进展。
Infect Dis Clin North Am. 2024 Sep;38(3):517-530. doi: 10.1016/j.idc.2024.04.006. Epub 2024 Jun 12.
2
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial.心血管风险和艾滋病毒（HIV）感染者的健康状况（适合初级预防）：来自 REPRIEVE 试验的见解。
Clin Infect Dis. 2021 Dec 6;73(11):2009-2022. doi: 10.1093/cid/ciab552.
3
Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE.在一项全球心血管疾病预防试验中，对感染艾滋病毒个体应用汇总队列方程和D:A:D风险评分的情况：一项利用REPRIEVE研究数据的队列研究
Lancet HIV. 2025 Feb;12(2):e118-e129. doi: 10.1016/S2352-3018(24)00276-5. Epub 2025 Jan 17.
4
Epidemiology of Antiretroviral Therapy Related Adverse Drug Reactions and its Predictors Among Patients with Human Immunodeficiency Virus/AIDS in Ethiopia: A Systematic Review and Meta-analysis.埃塞俄比亚人类免疫缺陷病毒/艾滋病患者中抗逆转录病毒疗法相关药物不良反应的流行病学及其预测因素：一项系统评价和荟萃分析
J Int Assoc Provid AIDS Care. 2025 Jan-Dec;24:23259582251358929. doi: 10.1177/23259582251358929. Epub 2025 Jul 15.
5
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis.抗逆转录病毒药物对“延缓艾滋病毒感染进程”（REPRIEVE）试验中主要不良心血管事件的影响：一项纵向队列分析
Lancet HIV. 2025 Jul;12(7):e496-e505. doi: 10.1016/S2352-3018(25)00043-8. Epub 2025 Jun 4.
6
Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial.在START（抗逆转录病毒治疗的战略时机）试验中，HIV阳性参与者立即与延迟启动抗逆转录病毒治疗时心血管疾病风险因素的变化。
J Am Heart Assoc. 2017 May 22;6(5):e004987. doi: 10.1161/JAHA.116.004987.
7
Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized Trial.接受匹伐他汀与安慰剂治疗以预防心血管疾病的 HIV 感染者的糖尿病风险因素：一项随机试验。
Ann Intern Med. 2024 Nov;177(11):1449-1461. doi: 10.7326/ANNALS-24-00944. Epub 2024 Oct 8.
8
Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel.他汀类药物治疗作为HIV感染者的一级预防：美国卫生与公众服务部抗逆转录病毒治疗指南小组建议概述
Ann Intern Med. 2025 Jun;178(6):847-857. doi: 10.7326/ANNALS-24-03564. Epub 2025 May 27.
9
Cardiovascular Risk in People Living with HIV: A Preliminary Case Study from Romania.罗马尼亚HIV感染者的心血管风险：一项初步案例研究。
Medicina (Kaunas). 2025 Aug 15;61(8):1468. doi: 10.3390/medicina61081468.
10
Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults.成人慢性未抑制的HIV感染中的结构化治疗中断（STI）
Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD006148. doi: 10.1002/14651858.CD006148.
引用本文的文献
1
Association of Cardiologist Clinic Visits With Cardiovascular Primary Prevention Outcomes Among People With HIV From Underrepresented Racial and Ethnic Groups in the Southern United States.美国南部代表性不足的种族和族裔群体中，心脏病专家门诊就诊与艾滋病毒感染者心血管疾病一级预防结果的关联。
J Am Heart Assoc. 2025 Mar 18;14(6):e038462. doi: 10.1161/JAHA.124.038462. Epub 2025 Mar 7.
2
Association of Cardiologist Clinic Visits with Cardiovascular Primary Prevention Outcomes Among People with HIV from Underrepresented Racial and Ethnic Groups in the Southern United States.美国南部少数族裔艾滋病毒感染者的心脏病专家门诊就诊与心血管疾病一级预防结局的关联
medRxiv. 2024 Aug 9:2024.08.08.24311709. doi: 10.1101/2024.08.08.24311709.
本文引用的文献
1
Nurse-Led Strategy to Improve Blood Pressure and Cholesterol Level Among People With HIV: A Randomized Clinical Trial.护士主导策略改善 HIV 感染者的血压和胆固醇水平：一项随机临床试验。
JAMA Netw Open. 2024 Mar 4;7(3):e2356445. doi: 10.1001/jamanetworkopen.2023.56445.
2
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial.吡咯烷二硫代氨基甲酸盐对 HIV 患者冠心病及炎症生物标志物的影响：REPRIEVE 随机临床试验的机制亚研究。
JAMA Cardiol. 2024 Apr 1;9(4):323-334. doi: 10.1001/jamacardio.2023.5661.
3
Time Trends in Causes of Death in People With HIV: Insights From the Swiss HIV Cohort Study.艾滋病毒感染者的死亡原因的时间趋势：来自瑞士艾滋病毒队列研究的见解。
Clin Infect Dis. 2024 Jul 19;79(1):177-188. doi: 10.1093/cid/ciae014.
4
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
5
Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association.纳入心血管-肾脏-代谢健康因素的全心血管疾病绝对风险评估新预测方程：美国心脏协会科学声明
Circulation. 2023 Dec 12;148(24):1982-2004. doi: 10.1161/CIR.0000000000001191. Epub 2023 Nov 10.
6
Association of SARS-CoV-2 Infection and Cardiopulmonary Long COVID With Exercise Capacity and Chronotropic Incompetence Among People With HIV.严重急性呼吸综合征冠状病毒 2 感染和心肺长新冠与艾滋病毒感染者运动能力和变时性功能不全的关联。
J Am Heart Assoc. 2023 Oct 17;12(20):e030896. doi: 10.1161/JAHA.123.030896. Epub 2023 Oct 13.
7
Cardiovascular health among persons with HIV without existing atherosclerotic cardiovascular disease.HIV 感染者的心血管健康：无现有动脉粥样硬化性心血管疾病。
AIDS. 2023 Nov 15;37(14):2179-2183. doi: 10.1097/QAD.0000000000003666. Epub 2023 Jul 26.
8
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.匹伐他汀预防 HIV 感染患者的心血管疾病。
N Engl J Med. 2023 Aug 24;389(8):687-699. doi: 10.1056/NEJMoa2304146. Epub 2023 Jul 23.
9
Out-of-Hospital Cardiac Arrest in Individuals With Human Immunodeficiency Virus: A Nationwide Population-Based Cohort Study.院外心脏骤停与人类免疫缺陷病毒感染者：一项全国范围内基于人群的队列研究。
Clin Infect Dis. 2023 Nov 30;77(11):1578-1584. doi: 10.1093/cid/ciad422.
10
Cardiology Encounters for Underrepresented Racial and Ethnic Groups with Human Immunodeficiency Virus and Borderline Cardiovascular Disease Risk.代表性不足的少数族裔人群与人类免疫缺陷病毒和边缘心血管疾病风险的心脏病学接触。
J Racial Ethn Health Disparities. 2024 Jun;11(3):1509-1519. doi: 10.1007/s40615-023-01627-0. Epub 2023 May 9.
Zotero 插件